Successful prophylaxis with recombinant human C1 inhibitor in a patient with hereditary angioedema.
暂无分享，去创建一个
[1] H. Farkas,et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency , 2014, Orphanet Journal of Rare Diseases.
[2] K. Obtulowicz,et al. Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study , 2013, Allergy.
[3] H. Farkas,et al. Short‐term prophylaxis in hereditary angioedema due to deficiency of the C1‐inhibitor – a long‐term survey , 2012, Allergy.
[4] R. Lockey,et al. WAO Guideline for the Management of Hereditary Angioedema , 2012, The World Allergy Organization journal.
[5] M. Cicardi,et al. Hereditary angio-oedema , 2012, The Lancet.
[6] H. Farkas,et al. rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency , 2011, Expert review of clinical immunology.
[7] A. Kaplan,et al. The plasma bradykinin-forming pathways and its interrelationships with complement. , 2010, Molecular immunology.
[8] P. Keith,et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.
[9] H. Farkas,et al. Recombinant human C1‐inhibitor in the treatment of acute angioedema attacks , 2007, Transfusion.